Your session is about to expire
← Back to Search
CMP-001 + Pembrolizumab for Squamous Cell Carcinoma
Study Summary
This trial is testing a new combination treatment for head and neck squamous cell carcinoma that consists of an intratumoral injection of CMP-001 followed by intravenous pembrolizumab. The goal is to see if this new treatment is more effective than pembrolizumab alone, and if it is well tolerated by participants.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with advanced head and neck cancer that cannot be cured with local treatments like surgery or radiation.Your disease can be treated locally with the goal of curing it.You have had progressive disease within three months of finishing treatment for advanced head and neck cancer.You currently have lung inflammation or have had lung inflammation in the past that required treatment with steroids.You have a condition that weakens your immune system.You have tumors that have spread to your brain or spinal cord and are causing symptoms or getting bigger, and you haven't received any treatment for them yet.You have received a transplant of tissue or organ from another person in the past.You may have HIV, hepatitis B, or hepatitis C, but we don't need to do a test to confirm it.You have a very short life expectancy (less than 3 months) or your disease is rapidly getting worse according to your doctor.You have already been treated with CMP-001 in the past.
- Group 1: CMP-001 and Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current enrollment for this research project?
"Presently, this trial is not admitting any more patients. The clinical trial was originally posted on 11/30/2020 and was most recently edited on 11/11/2022. If you are seeking for other studies, there are presently 2761 studies actively admitting patients with oral squamous cell carcinoma and 1000 trials for Pembrolizumab actively enrolling patients"
In how many places can people participate in this clinical trial?
"Currently, this trial is being conducted at 19 sites which include locations such as Iowa City, Houston and Little Rock. To reduce travel burdens, patients are encouraged to select the site nearest them."
What is the precedence for using Pembrolizumab in medical treatments?
"Pembrolizumab is being studied in 1000 different clinical trials, 122 of which are currently recruiting patients. Many of the Pembrolizumab trials began in Houston, Texas; however, there are 36025 total locations for these studies."
Is Pembrolizumab known to have harmful side effects?
"Pembrolizumab falls into the Phase 2 category, meaning that while there is some evidence of its safety, none exists for efficacy. Our team power estimated a score of 2."
Are patients currently being enrolled in this clinical trial?
"Unfortunately, this study is no longer recruiting patients. The original posting was on November 30th 2020 but the listing was edited for the last time on November 11th 2022. However, there are 2761 other trials involving oral squamous cell carcinoma and 1000 studies that use Pembrolizumab currently admitting patients."
What are some of the conditions that Pembrolizumab has been shown to be effective against?
"Pembrolizumab is a medication that oncologists often prescribe to cancer patients. In addition to its efficacy in treating malignant neoplasms, pembrolizumab can also help patients with unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."
Share this study with friends
Copy Link
Messenger